Therefore, the peptide-based PD1 inhibitors would not just provide an adjuvant effect for the T-cell; it would also alleviate the existing T-cell exhaustion that results from an ongoing heavy load of infection and allow the T cells to be responsive to the vaccine antigens. This evidence concerns the gene PDCD1 and infection.